VIDEO: Oral selective estrogen receptor degrader may benefit some breast cancer patients
In this video, Sara M. Tolaney, MD, MPH, discussed updated data from the phase I SERENA-1 trial,which was presented at the virtual San Antonio Breast Cancer Symposium.
According to Tolaney, an assistant professor of medicine at Harvard Medical School and a breast medical oncologist with Dana-Farber Cancer Institute, endocrine resistance is a “common” issue among patients with endocrine receptor positive breast cancer.
Unlike the intramuscular agent fulvestrant (Faslodex; AstraZeneca), the current first-line option for selective estrogen receptor degrader (SERD) therapy, AZD9833 (AztraZeneca), studied in SERENA-1, is an oral agent.
“The idea behind an oral SERD is that not only would it be more convenient, because it would be oral, but also would be able to potentially achieve higher drug exposures, really increase ER degradation and hopefully improve clinical benefit,” she said.
Collapse
Baird R. Poster PS11-05. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Read more about